Neridronate for Complex Regional Pain Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
A Phase 3 open-label extension study of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
Who Is on the Research Team?
Gail Cawkwell, MD, PhD
Principal Investigator
Ambros Therapeutics, Inc.
Are You a Good Fit for This Trial?
This trial is for people with Complex Regional Pain Syndrome Type 1 who finished a previous neridronate study, are not pregnant or breastfeeding, can use effective birth control, have good vein access for IV infusions and blood tests, and are able to follow the treatment plan.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Neridronate
Trial Overview
The study is testing ongoing treatment with neridronate (AMBTX-01) given by IV infusion to see if it helps manage pain in people with CRPS Type 1. All participants receive the drug; there is no placebo group.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
400 mg AMBTX-01 infusion
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ambros Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.